lerts History
- 23-Feb-2017 14:51:49 - AIRBUS AIR.PA CALLS FOR EUROPEAN MINISTERIAL MEETING TO DISCUSS LATEST A400M COST CRISIS - SOURCES
- 23-Feb-2017 14:52:23 - AIRBUS ALSO CALLS FOR TALKS WITH A400M ENGINE MANUFACTURERS - SOURCES
- 23-Feb-2017 14:52:43 - AIRBUS SAYS IN LETTER IT IS COMMITTED TO A400M PROJECT BUT MUST 'SUSTAIN THE VIABILITY OF AIRBUS' -SOURCES
EXCLUSIVE-Airbus calls for European ministerial meeting on A400M - Reuters News
23-Feb-2017 15:03:24
Feb 23 (Reuters) - Airbus AIR.PA has called for a European ministerial meeting to address the latest problems engulfing the A400M military plane, saying its own viability is at stake as it seeks government help to contain fresh losses on Europe's largest defence project.
The move comes a day after Airbus took a fresh writedown of 1.2 billion euros against A400M losses and urged seven NATO buyer nations to limit its exposure to heavy fines and payment delays caused by new technical snags and delays. (Full Story)
In a letter to government buyers, the company spoke of "significant risks ahead" on the project, originally valued at 20 billion euros and now costing well over 30 billion euros, according to two people familiar with the letter's contents.
"We are committed to the A400M programme. However we are responsible to sustain the viability of Airbus," said the letter signed by Airbus Chairman Denis Ranque and Chief Executive Tom Enders and sent to the capitals of Belgium, France, Germany, Luxembourg, Spain and Turkey and the UK.
Noting "huge losses" on the project, Airbus called for a meeting of ministers of those nations to take stock of the situation and agree on next steps in the best interests of the programme, government customers and Europe's defence industry.
It also called for talks with Europrop International (EPI), the consortium responsible for providing the troop carrier's turboprop engines, which have been involved in some delays.
EPI is owned by France's Safran SAF.PA, Britain's Rolls-Royce RR.L, Germany's MTU Aero Engines MTXGn.DE and Industria de Turbo Propulsores (ITP) of Spain.
An Airbus spokeswoman declined comment on Thursday on details of the company's contacts with governments, but said there would be three elements to any discussions: the nations, the OCCAR pan-European procurement agency and the engine makers.
Engine consortium EPI could not immediately be reached for comment.
A spokesman for OCCAR had said on Wednesday the agency was in regular and ongoing dialogue with Airbus, but declined comment on the company's request for new measures.
Airbus received a 3.5 billion euro bailout from the seven core purchasing nations in 2010, but has suggested it did not go far enough in limiting the company's financial exposure.
Defence officials from the seven nations were expected to confer by telephone on Airbus requests as early as Thursday.
Germany, the largest A400M buyer, has so far given a cool response, saying it is important that Airbus should resolve outstanding problems on the military programme. (Full Story)
In reaction to strong earnings/guidance:
- CBMX +19.5%, CPG +14.3%, UCTT +12.1%, TGB +10.7%, CRI +9.5%, SQ +9%, SBGL +7.8%, SPAR +7.8%, DOOR +6.6%, TRNC +5.8%, DNR +5.8%
- CTRP +5.1%, OAS +4.7%, CRZO +3.8%, VC +3.7%, RIG +3.4%,COTV +3.3%, IAG +3.2%, OCN +2.8%, HL +2.8%, GDOT +2.7%,ZBRA +2.6%, TEF +2.5%
- RGR +2.4%, CHK +2.4%, KSS +2.4%, WPX +2.3%, SXL +2.2%, HPQ +1.9%, ETP +1.8%, RRC +1.7%, SAIC +1.7%, PRAH +1.4%, DMRC +1.4%, CNK +1.4%
- CLR +1.2%, LTC +1.1%, TFX +1.1%, VALE +1.1%, APA +1.1%,TCAP +1%, JAKK +1%, MYGN +1%
- IAG +3.2%, AUY +2.5%, AU +2.4%, AG +1.5%, BBL +1.2%, SLW+1%, BHP +0.8%
- SDRL +3.4%, NOV +2.3%, PBR +1.9%, MRO +1.5%, COP +1.4%,HES +1.3%, BP +1.2%, KMI +1.2%, HAL +1.1%
- PTX +40.1% (receives a favorable opinion in its litigation with Actavis Laboratories FL, Inc. regarding a proposed generic version of Zohydro ER)
- NAK +33.1% (rebounding from yesterday's move lower; comments on US House Committee on Science, Space and Technology letter to EPA Administrator to withdraw Pebble Project veto)
- AVEO +19.2% (Phase 3 TIVO-3 trial to compare tivozanib to sorafenib in subjects with refractory advanced renal cell carcinoma has successfully completed the first safety review by the study's Safety Monitoring Committee)
- URRE +12.6% (reports 'favorable' lithium concentrations at the Columbus Basin Project )
- INO +7.6% (presents positive clinical data on Inovio's DNA-based vaccines against MERS)
- ASPS +4.5% (continued strength after the CEO disclosed purchase of 5,250 shares)
- TRXC +3.1% (launched commercial operations and completed its first sale of the Senhance Surgical System in Germany)
- FNMA +2.3% (Fairholme provides update on Fannie Mae and Freddie Mac)
- MT +2% (ArcelorMittal Brasil and Votorantim sign agreement to combine their Brazilian long steel businesses)
- FMCC +1.4% (Fairholme provides update on Fannie Mae and Freddie Mac)
- SHPG +1.4% (publication of results from the Phase 1b study of lanadelumab in NEJM)
- NTES +1.2% (following SINA results)
- TIF +1% (JANA Partners filed a 13D confirming its 4.9% active stake)
- SHOO +2.8% (upgraded to Overweight from Neutral at Piper Jaffray)
- WAAS +2.7% (upgraded to Strong Buy from Outperform at Raymond James)
- PI +2.3% (initiated with a Overweight at Morgan Stanley)
- HD +0.9% (upgraded to Overweight from Equal-Weight at Morgan Stanley)
- RETA +0.6% (initiated with a Buy at Stifel)
In reaction to disappointing earnings/guidance:
- ORIG -28.7%, (continues to explore alternatives-will consider all options including restructuring plan through schemes of arrangement or under Chapter 11)
- ARRS -15.3%, (Arris and Broadcom announce that they have entered into an agreement for ARRIS to acquire Brocade Communication Systems Inc.'s (BRCD) Ruckus Wireless and ICX Switch business for cash consideration of $800 mln; expected to be accretive in first 12 mos)
- LB -13.8%, TSRA -13.5%, HBM -10.2%, JACK -9.4%, AFH -8.4%,SAM -6.8%, ELGX -5.8%, CSGP -5.5%, FMI -5.3%, HRL -4.8%, SGC -4.7%, CVEO -4.3%
- IRDM -3.8%, W -3.6%, EVA -3.4%, COMM -3.2%, QEP -2.7%, SAFM -2.6%, TSLA -2.4%, (also CFO stepping down to pursue position in public policy), WB -2.4%
- LGCY -2.4%, AAON -2.3%, BCS -2.1%, INOV -1.8%, SAGE -1.5%,CHSP -1.2%, LDOS -1.2%, SM -1.2%, CSAL -1.1%
- CYCC -34% (Phase 3 SEAMLESS study in elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia did not meet its primary endpoint)
- CLD -8.8% (prices offering of 13,500,000 shares of common stock at $5.10 per share)
- APAM -5.6% ( commences 5,626,517 common stock offering)
- MYSZ -4.9% (discloses entry into Securities Purchase Agreement with an accredited investor)
- GPS -1.9% (following LB results)
- NTB -1.8% (prices a registered secondary offering by certain selling shareholders of 9,555,794 of Butterfield's voting ordinary shares at a price of $31.75/share)
- NGD -1.3% (announces bought deal financing for 53.6 mln common shares at $2.80/share)
- AKAO -0.8% (achieves a strategic milestone in their ongoing efforts to develop an assay enabling therapeutic drug management of plazomicin), .
- NVDA -3.8% (downgraded to Underperform from Market Perform at BMO Capital Markets)
- BLMN -2.1% (downgraded to Neutral from Outperform at Credit Suisse)
- LE -1.5% (downgraded to Hold from Buy at Craig Hallum)